Avaliação da cardiomiopatia

Last reviewed: 20 Aug 2025
Last updated: 30 Jul 2025

Summary

Differentials

Common

  • Cardiomiopatia dilatada idiopática
  • Miocardite
  • Bebidas alcoólicas: cardiomiopatia dilatada
Full details

Uncommon

  • Cardiomiopatia hipertrófica (CMH)
  • Cardiomiopatia restritiva idiopática
  • Cardiomiopatia arritmogênica do ventrículo direito
  • Síndrome de Brugada e outras canalopatias iônicas
  • Doença do sistema de condução
  • Distúrbios mitocondriais
  • Síndrome do takotsubo
  • Periparto: cardiomiopatia dilatada
  • Induzida por taquicardia: cardiomiopatia dilatada
  • Amiloidose: cardiomiopatia hipertrófica ou restritiva
  • Hemocromatose: cardiomiopatia restritiva ou dilatada
  • Doença de Fabry: cardiomiopatia restritiva ou hipertrófica
  • Outras doenças do armazenamento lisossomal
  • Doxorrubicina: cardiomiopatia dilatada
  • Metais pesados/substâncias químicas: cardiomiopatia dilatada
  • Diabetes mellitus
  • Disfunção tireoidiana: cardiomiopatia dilatada
  • Acromegalia: cardiomiopatia hipertrófica ou dilatada
  • Síndrome de Noonan: cardiomiopatia hipertrófica
  • Lentiginose: cardiomiopatia hipertrófica
  • Deficiência de tiamina (beribéri úmido): cardiomiopatia dilatada
  • Ataxia de Friedreich/distrofia muscular: cardiomiopatia hipertrófica e dilatada
  • Deficiência de ferro, niacina, selênio ou vitamina D: cardiomiopatia dilatada
  • Lúpus eritematoso sistêmico: cardiomiopatia dilatada
  • Fibrose endomiocárdica/endocardite de Loeffler (síndrome hipereosinofílica)
  • Sarcoidose
  • Distúrbios eletrolíticos
Full details

Contributors

Authors

Katie Linden, BMSc, MBChB

Cardiology Specialty Registrar

Belfast Health and Social Care Trust

Belfast

Northern Ireland

Disclosures

KL was reimbursed by Takeda UK Ltd., the manufacturer of Replagal for Fabry disease, for travel and accommodation for a leadership course. KL was reimbursed by Sanofi Aventis, the manufacturer of Genzyme for Fabry disease, for travel and accommodation for a conference. KL received a speaker fee from Sanofi Aventis, the manufacturer of Genzyme, for a talk on Fabry disease. There was no contractual right by Sanofi to control the content of this talk.

Alison Muir, MD

Consultant Cardiologist

Royal Victoria Hospital

Belfast Health and Social Care Trust

Belfast

UK

Disclosures

AM is an author of a reference cited in this topic.

Acknowledgements

KL and AM would like to gratefully acknowledge Dr Pascal McKeown, a previous contributor to this topic. PM is an author of a reference cited in this topic.

Peer reviewers

Lubna Choudhury, MB BCh, MD, MRCPI, FACC

Professor of Medicine

Division of Cardiology

Northwestern University

Chicago

IL

Disclosures

LC declares that she has no competing interests.

John Coltart, MD, FRCP, FACC, FESC, MRCS

Consultant Cardiologist

Cardio-thoracic Unit

Guy's and St Thomas' Hospital

London

UK

Disclosures

JC declares that he has no competing interests.

Vaikom S. Mahadevan, MBBS, MRCP

Consultant Cardiologist

Manchester Royal Infirmary

Manchester

UK

Disclosures

VSM declares that he has no competing interests.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

References

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Key articles

Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC guidelines for the management of cardiomyopathies. Eur Heart J. 2023 Oct 1;44(37):3503-626.Full text  Abstract

Ommen SR, Ho CY, Asif IM, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association/American College of Cardiology joint committee on clinical practice guidelines. Circulation. 2024 Jun 4;149(23):e1239-311.Full text  Abstract

Nagueh SF, Phelan D, Abraham T, et al. Recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy: an update from the American Society of Echocardiography, in collaboration with the American Society of Nuclear Cardiology, the Society for Cardiovascular Magnetic Resonance, and the Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr. 2022 Jun;35(6):533-69.Full text  Abstract

American College of Radiology. ACR appropriateness criteria: nonischemic myocardial disease with clinical manifestations. 2020 [internet publication].Full text

British Society of Echocardiography. Diagnosis and assessment of dilated cardiomyopathy: a guideline protocol from the British Society of Echocardiography. Jun 2017 [internet publication].Full text

Reference articles

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
  • Avaliação da cardiomiopatia images
  • Guidelines

    • 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association/American College of Cardiology joint committee on clinical practice guidelines
    • Management of cardiomyopathies
    More Guidelines
  • Patient information

    Insuficiência cardíaca: como posso me ajudar?

    Insuficiência cardíaca

    More Patient information
  • Videos

    Galope de terceira bulha cardíaca

    Galope de quarta bulha cardíaca

    More videos
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer